PMID- 18577155
OWN - NLM
STAT- MEDLINE
DCOM- 20090402
LR  - 20151119
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 10 Suppl 2
DP  - 2008 Jul
TI  - Insulin therapy in elderly patients with type 2 diabetes: the role of insulin 
      glargine.
PG  - 35-41
LID - 10.1111/j.1463-1326.2008.00843.x [doi]
AB  - Within the USA, between 1980 and 2005, the prevalence of diagnosed diabetes has 
      increased in all age groups, with the age group 65-74 years having the highest 
      prevalence. The treatment of type 2 diabetes mellitus (T2DM) in elderly people is 
      made more difficult than in their younger counterparts, primarily owing to the 
      impact of co-morbidities, complications and hypoglycaemia as well as technical 
      difficulties with insulin injections. Accordingly, the treatment approach for 
      elderly patients with T2DM may need to be modified to accommodate co-morbidities 
      and illnesses associated with ageing. Risks associated with insulin therapy, 
      particularly hypoglycaemia, have traditionally limited the use of insulin in this 
      patient population. Insulin glargine is associated with a low risk of 
      hypoglycaemia compared with neutral protamine Hagedorn insulin, for example, and 
      could thus provide a treatment of choice for healthcare providers when 
      considering the increasing prevalence of diabetes in the elderly population. A 
      regimen based on insulin glargine plus oral agents provides clinicians with a 
      tool to help meet therapeutic targets in this population without increasing risk 
      of hypoglycaemia.
FAU - Janka, H U
AU  - Janka HU
AD  - Klinikum Bremen-Nord, Bremen, Germany. hans.janka@klinikum-bremen-nord.de
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin, Long-Acting)
RN  - 2ZM8CX04RZ (Insulin Glargine)
SB  - IM
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemia/chemically induced/epidemiology
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Insulin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Insulin Glargine
MH  - Insulin, Long-Acting
RF  - 43
EDAT- 2008/07/17 09:00
MHDA- 2009/04/03 09:00
CRDT- 2008/07/17 09:00
PHST- 2008/07/17 09:00 [pubmed]
PHST- 2009/04/03 09:00 [medline]
PHST- 2008/07/17 09:00 [entrez]
AID - DOM843 [pii]
AID - 10.1111/j.1463-1326.2008.00843.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2008 Jul;10 Suppl 2:35-41. doi: 
      10.1111/j.1463-1326.2008.00843.x.